News

Vaccinogen Names Dr. Ben Carson and Dr. Jan B. Vermorken to Medical Advisory Board


Learn More >>

Vaccinogen Announces SEC Clearance of Form 10 Registration Statement and Upgrade to OTC.QB Market


Learn More >>

On December 5th, Dr. Hanna presented at the LifeScience R&D Big Data Leaders Forum held in Basel, Switzerland

Watch >>


Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development

Learn More >>

Near-Term Revenues

Vaccinogen believes this novel asset, the B-cell collection, and potentially materials developed during the 8701 trial and predecessor company efforts, represent a valuable asset that can generate significant upfront fees, development milestones and royalties via collaborations and licensing activities that will complement the OncoVAX® investment opportunity.

Learn More >>

FDA Approval

FDA

Special Protocol Assessment
Learn More >>

Fast Track
Learn more >>

Publications

Human Vaccines 2006
Active Specific Immunotherapy with Autologous Tumor Cell Vaccines
Learn more >>

Cancer Vaccine Space

Vaccinogen is uniquely positioned within the cancer vaccine space
Learn more >>

Site credit: idfive, the interactive division of growth5